Joshua Roy Basler, Palo Alto, CA (US); Michael Stoner, San Jose, CA (US); James T. Kellis, Jr., Woodside, CA (US); Adam Garske, Palo Alto, CA (US); David Marquez, San Jose, CA (US); Katherine Augustyn, San Francisco, CA (US); Priyanka Chandrasekaran, Brisbane, CA (US); Miles Christopher Scotcher, San Ramon, CA (US); Lilia Maria Babe, Emerald Hills, CA (US); Richard R. Bott, Kirkland, WA (US); David A. Estell, San Mateo, CA (US); Gudrun Vogtentanz, Sunnyvale, CA (US); Sina Pricelius, Leiden (NL); and Jian Yao, Sunnyvale, CA (US)
Assigned to Danisco US Inc., Palo Alto, CA (US)
Filed by DANISCO US INC., Palo Alto, CA (US)
Filed on Apr. 17, 2023, as Appl. No. 18/301,460.
Application 18/301,460 is a division of application No. 16/305,259, granted, now 11,661,567, previously published as PCT/US2017/035217, filed on May 31, 2017.
Claims priority of provisional application 62/343,618, filed on May 31, 2016.
Prior Publication US 2024/0093124 A1, Mar. 21, 2024
1. A subtilisin variant comprising an amino acid sequence comprising an amino acid substitution of T77N-G165Q, wherein said variant has at least 90% amino acid sequence identity to the amino acid sequence of a parent subtilisin comprising the amino acid sequence of SEQ ID NO:2, wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO:2, wherein the variant has protease activity measured by hydrolysis of N-succinyl-alanine-alanine-proline-phenylalanine-p-nitroanilide (N-suc-AAPF-pNA) or dimethyl casein substrate, and wherein the variant has improved stability in a boron-free detergent when compared to stability in a boron-free detergent of said parent subtilisin.